Caesars Entertainment misses Q2 earnings expectations, shares edge lower
Semler Scientific (NASDAQ:SMLR), Inc., a $456 million medical technology company currently trading at $40.88, has announced the addition of Ms. Natalie Brunell to its Board of Directors, effective immediately. The appointment comes as the company’s stock shows strong momentum, gaining over 17% in the past week. On Sunday, the company’s Board, following the Nominating and Corporate Governance Committee’s recommendation, appointed Ms. Brunell as a Class II director. She will serve in this role until the 2026 annual meeting of stockholders.
Ms. Brunell’s appointment fills a newly created vacancy on the Board, expanding the number of directors to five. In addition to her director role, she will also join the Bitcoin Strategy Committee. According to InvestingPro, analysts maintain a strong buy rating on the stock with a price target of $71, suggesting significant upside potential.
As part of her compensation for joining mid-year, Ms. Brunell received a pro-rated grant of 7,500 stock options for her Board service and 1,875 options for her committee service, pursuant to the company’s non-employee director compensation policy. These options are part of the Semler Scientific, Inc. 2024 Stock Option and Incentive Plan, with varying vesting schedules and expiration dates.
Semler Scientific has entered into a standard indemnification agreement with Ms. Brunell, ensuring protection under certain circumstances as detailed in their filings. There are no disclosed transactions or relationships that would require reporting under SEC Regulation S-K, Item 404(a).
This announcement is based on a press release statement. The company maintains impressive gross profit margins of 91% and is expected to return to profitability this year. For a comprehensive analysis of Semler Scientific’s financial health and growth prospects, access the detailed Pro Research Report available exclusively on InvestingPro, along with 12 additional key insights about the company’s performance.
In other recent news, Semler Scientific reported a net loss of $64.7 million for the first quarter of 2025, with earnings per share at -$6.74. The company’s revenue fell by 44% year-over-year, totaling $8.8 million. Despite these financial challenges, Semler Scientific continues to focus on its Bitcoin treasury strategy, having accumulated 3,808 Bitcoins valued at approximately $400 million. The company has ambitious plans to further increase its Bitcoin holdings, supported by a $500 million ATM program. Additionally, Semler Scientific is expanding its efforts in the cardiovascular market with its QuantaFlo product, which is pending new 510(k) clearance for broader medical use. The company is also navigating pressures from CMS payment changes and reduced PAD testing volumes. In a strategic move, Semler Scientific appointed Natalie Brunell, a prominent figure in the Bitcoin community, to its board of directors. This appointment aims to enhance the company’s Bitcoin strategy as they continue to leverage their healthcare business to generate cash for Bitcoin acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.